# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older

The following tables provide guidance for COVID-19 vaccination schedules based on age and medical condition and vaccine composition.

### Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age*

| Type | Recipient Age | Product† | For Most People | | Those Who **ARE** Moderately or Severely Immunocompromised | |
|---|---|---|---|---|---|---|
| | | | Doses | Interval Between Doses‡ | Doses | Interval Between Doses |
| mRNA vaccine | 6 months through 5 years§ | **MONOVALENT Moderna:** Blue vial cap with magenta-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 4–8 weeks¶ | Dose 1 to 2 | At least 4 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | 6 through 11 years | **MONOVALENT Moderna:** Blue vial cap with purple-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 4–8 weeks¶ | Dose 1 to 2 | At least 4 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | | **BIVALENT Moderna:** Blue vial cap with gray-bordered label | Booster dose: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 3 to 4 | At least 8 weeks (2 months) |
| | 12 through 17 years | **MONOVALENT Moderna:** Red vial cap with blue-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 4–8 weeks¶ | Dose 1 to 2 | At least 4 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | | **BIVALENT Moderna:** Blue vial cap with gray-bordered label | Booster dose: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 3 to 4 | At least 8 weeks (2 months) |
| | 6 months through 4 years | **MONOVALENT Pfizer-BioNTech:** Maroon vial cap with maroon-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 3–8 weeks¶ | Dose 1 to 2 | At least 3 weeks |
| | | | Doses 2 and 3 | At least 8 weeks (2 months) | Dose 2 to 3 | At least 8 weeks (2 months) |
| | 5 through 11 years | **MONOVALENT Pfizer-BioNTech:** Orange vial cap with orange-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 3–8 weeks¶ | Dose 1 to 2 | At least 3 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | | **BIVALENT Pfizer-BioNTech:** Orange vial cap with orange-bordered label | Booster dose: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 3 to 4 | At least 8 weeks (2 months) |
| | 12 years through 17 years | **MONOVALENT Pfizer-BioNTech:** Gray vial cap with gray-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 3-8 weeks¶ | Dose 1 to 2 | At least 3 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | | **BIVALENT Pfizer-BioNTech:** Gray vial cap with gray-bordered label | Booster dose: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 3 to 4 | At least 8 weeks (2 months) |
| Protein subunit vaccine | 12 years and older | **MONOVALENT Novavax** | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 3–8 weeks¶ | Dose 1 to 2 | At least 3 weeks |
| | | mRNA (Moderna, Pfizer-BioNTech) should be used for the booster dose. | Booster dose: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 2 to 3 | At least 8 weeks (2 months) |

* Guidance related to special situations when vaccinating children, such as those who have a birthday before completing the primary series or booster dose, see Special Situations for COVID-19 Vaccination of Children and Adolescents

† Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the bivalent booster dose, regardless of the primary series product.

‡ Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

§ Administer 1 Pfizer Bio-NTech bivalent booster dose to children age 5 years who have completed a primary series of Moderna COVID-19 vaccine.

¶ An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older

## Table 2. Immunization Schedule for Persons 18 Years of Age

| Type | Recipient Age | Product* | For Most People | | Those Who **ARE** Moderately or Severely Immunocompromised | |
|---|---|---|---|---|---|---|
| | | | Doses | Interval Between Doses† | Doses | Interval Between Doses |
| mRNA vaccine | 18 years and older | **MONOVALENT Moderna** Red vial cap with a blue-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 4–8 weeks‡ | Dose 1 to 2 | At least 4 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | | **BIVALENT Moderna** Blue cap with gray-bordered label | Booster dose§: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 3 to 4 | At least 8 weeks (2 months) |
| | 18 years and older | **MONOVALENT Pfizer-BioNTech** Gray vial cap with gray-bordered label | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 3-8 weeks‡ | Dose 1 to 2 | At least 3 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | | **BIVALENT Pfizer-BioNTech:** Gray vial cap with gray-bordered label | Booster dose§: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 3 to 4 | At least 8 weeks (2 months) |
| Protein subunit vaccine | 18 years and older | **MONOVALENT Novavax** | Primary series: Monovalent | | | |
| | | | Dose 1 to 2 | At least 3–8 weeks‡ | Dose 1 to 2 | At least 3 weeks |
| | | Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose. | Booster dose§: Bivalent | | | |
| | | | Dose 2 to 3 | At least 8 weeks (2 months) | Dose 2 to 3 | At least 8 weeks (2 months) |
| Adenovius vector vaccine | 18 years and older | **MONOVALENT Janssen** | Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations.¶ | | | |
| | | Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose. | Booster dose§: Bivalent | | | |
| | | | Administer a single booster dose at least 8 weeks (2 months) after the previous dose. | | | |

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the booster dose, regardless of the primary series product.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

§ A single Novavax booster dose (instead of a bivalent mRNA booster dose) may be given to persons 18 years of age or older who have not received a previous booster dose in **limited situations**. These situations are 1. an mRNA vaccine is contraindicated, or not available or 2. the recipient is unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. Administer the booster dose at least 6 months after the last primary series dose.

¶ For guidance on use of Janssen vaccine and retrospective record review, scheduling and administration see Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A

## CDC Resources

CDC COVID-19 vaccine clinical training and materials

CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

CDC Vaccine administration clinical materials

*CDC Vaccine Storage and Handling Toolkit*

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older

- Administer the correct vaccine product based on the recipient's age and vaccine composition.
- COVID-19 vaccines may be administered on the same day as other routinely recommended vaccines, including influenza vaccine.

### Table 3. COVID-19 Vaccine Products Summary

| Type | Product* | Age Indications† | Diluent | Use For: | Dose/Injection Amount |
|---|---|---|---|---|---|
| mRNA vaccine | **MONOVALENT Moderna:** Blue vial cap with magenta-bordered label | 6 months through 5 years | NONE | Any dose in the primary series | 25 μg/ 0.25 mL |
| | **MONOVALENT Moderna:** Blue vial cap with purple-bordered label | 6 through 11 years | NONE | Any dose in the primary series | 50 μg/0.5 mL |
| | **BIVALENT Moderna:** Blue vial cap with gray-bordered label | 6 through 11 years | NONE | Booster dose | 25 μg/0.25 mL |
| | **MONOVALENT Moderna:** Red vial cap with blue- bordered label | 12 years and older | NONE | Any dose in the primary series | 100 μg/ 0.5 mL |
| | **BIVALENT Moderna:** Blue vial cap with gray-bordered label | 12 years and older | NONE | Booster dose | 50 μg/0.5 mL |
| | **MONOVALENT Pfizer-BioNTech:** Maroon vial cap with maroon-bordered label | 6 months through 4 years | 2.2 mL 0.9% sodium chloride (normal saline, preservative-free) | Any dose in the primary series | 3 μg/0.2 mL |
| | **MONOVALENT Pfizer-BioNTech:** Orange vial cap with orange-bordered label | 5 through 11 years | 1.3 mL 0.9% sodium chloride (normal saline, preservative-free) | Any dose in the primary series | 10 μg/0.2 mL |
| | **BIVALENT PFIZER-BIONTECH** Orange vial cap with a orange-bordered label | 5 through 11 years | 1.3 mL 0.9% sodium chloride (normal saline, preservative-free) | Booster dose | 10 μg/0.2 mL |
| | **MONOVALENT Pfizer-BioNTech:** Gray vial cap with a gray- bordered label | 12 years and older | NONE | Any dose in the primary series | 30 μg/0.3 mL |
| | **BIVALENT Pfizer-BioNTech:** Gray vial cap with gray-bordered label | 12 years and older | NONE | Booster dose | 30 μg/0.3 mL |
| Protein sub unit vaccine | **MONOVALENT Novavax:** Royal blue cap | 12 years and older | NONE | Any dose in the primary series or as a single booster dose, in **limited situations**, for persons 18 years of age or older | 5 μg rS and 50 μg of Matrix-M™ adjuvant/0.5 mL |
| Viral vector vaccine | **MONOVALENT Janssen:** Blue Cap | 18 years and older | NONE | Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations.‡ | 5×1010 viral particles/0.5 mL |

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Age-appropriate Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the booster dose, regardless of the primary series product.

† Administer the appropriate vaccine product based on the recipient's age and the vaccine product's age indications.

‡ For guidance on use of Janssen vaccine and retrospective record review, scheduling and administration see Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A